Search

Your search keyword '"Viqueira, Andrea"' showing total 49 results
Start Over Author "Viqueira, Andrea" Language english
49 results on '"Viqueira, Andrea"'

1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Author

Lesokhin, Alexander M., Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Miles Prince, H., Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Touzeau, Cyrille, Jethava, Yogesh, Quach, Hang, Depaus, Julien, Yokoyama, Hisayuki, Gabayan, Afshin Eli, Stevens, Don A., Nooka, Ajay K., Manier, Salomon, Raje, Noopur, Iida, Shinsuke, Raab, Marc-Steffen, Searle, Emma, Leip, Eric, Sullivan, Sharon T., Conte, Umberto, Elmeliegy, Mohamed, Czibere, Akos, Viqueira, Andrea, and Mohty, Mohamad

Published
2023
Full Text
View/download PDF

3. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Author

Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, and Deininger, Michael W.

Published
2022
Full Text
View/download PDF

7. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Author

Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Abboud, Camille, Gjertsen, Bjørn Tore, Brümmendorf, Tim H., Smith, B. Douglas, Ernst, Thomas, Giraldo-Castellano, Pilar, Olsson-Strömberg, Ulla, Saussele, Susanne, Bardy-Bouxin, Nathalie, Viqueira, Andrea, Leip, Eric, Russell-Smith, T. Alexander, Leone, Jocelyn, Rosti, Gianantonio, Watts, Justin, and Giles, Francis J.

Published
2020
Full Text
View/download PDF

9. Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Author

Bahlis, Nizar Jacques, Tomasson, Michael H., Mohty, Mohamad, Niesvizky, Ruben, Nooka, Ajay K., Manier, Salomon, Maisel, Christopher, Jethava, Yogesh, Martinez-Lopez, Joaquin, Prince, H Miles, Arnulf, Bertrand, Rodriguez Otero, Paula, Koehne, Guenther, Touzeau, Cyrille, Raje, Noopur, Iida, Shinsuke, Raab, Marc-Steffen, Leip, Eric, Sullivan, Sharon, Conte, Umberto, Viqueira, Andrea, and Lesokhin, Alexander M

Published
2022
Full Text
View/download PDF

20. MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study

Author

Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Prince, H. Miles, Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Jethava, Yogesh, Gabayan, Afshin E., Stevens, Don A., Nooka, Ajay K., Raje, Noopur, Iida, Shinsuke, Leip, Eric, Conte, Umberto, Czibere, Akos, Viqueira, Andrea, and Lesokhin, Alexander M.

Published
2023
Full Text
View/download PDF

21. MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies

Author

Nooka, Ajay K., Lesokhin, Alexander M., Mohty, Mohamad, Niesvizky, Ruben, Maisel, Christopher, Arnulf, Bertrand, Larson, Sarah M., Varshavsky-Yanovsky, Asya Nina, Leleu, Xavier, Karlin, Lionel, Vesole, David H., Bahlis, Nizar J., de Larrea, Carlos Fernández, Raje, Noopur, Leip, Eric, Conte, Umberto, Elmeliegy, Mohamed, Viqueira, Andrea, and Manier, Salomon

Published
2023
Full Text
View/download PDF

22. POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study

Author

Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Prince, H. Miles, Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Jethava, Yogesh, Gabayan, Afshin E., Stevens, Don A., Nooka, Ajay K., Raje, Noopur, Iida, Shinsuke, Leip, Eric, Conte, Umberto, Czibere, Akos, Viqueira, Andrea, and Lesokhin, Alexander M.

Published
2023
Full Text
View/download PDF

24. POSTER: MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)- Directed Therapies: Pooled Analysis From MagnetisMM Studies

Author

Nooka, Ajay K., Lesokhin, Alexander M., Mohty, Mohamad, Niesvizky, Ruben, Maisel, Christopher, Arnulf, Bertrand, Larson, Sarah M., Varshavsky-Yanovsky, Asya Nina, Leleu, Xavier, Karlin, Lionel, Vesole, David H., Bahlis, Nizar J., de Larrea, Carlos Fernández, Raje, Noopur, Leip, Eric, Conte, Umberto, Elmeliegy, Mohamed, Viqueira, Andrea, and Manier, Salomon

Published
2023
Full Text
View/download PDF

26. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.

Author

Muresan, Bogdan, Mamolo, Carla, Cappelleri, Joseph C., Leip, Eric, Viqueira, Andrea, and Heeg, Bart

Subjects
DASATINIB, NILOTINIB, CHRONIC myeloid leukemia, PROTEIN-tyrosine kinases, THERAPEUTIC use of antineoplastic agents, QUINOLINE, PROTEIN kinase inhibitors, HETEROCYCLIC compounds, ORGANIC compounds, TREATMENT effectiveness, AMINES
Abstract

Objective: Bosutinib, nilotinib and dasatinib are approved for the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). In the absence of head-to-head comparisons between second-generation tyrosine kinase inhibitors (TKIs), the objective of this study was to indirectly compare the efficacy of bosutinib with nilotinib and dasatinib in first-line (1L) CP-CML.Methods: Cross-trial heterogeneity in terms of patient baseline characteristics and imatinib dose escalation are difficult to adjust for in network meta-analyses and anchored matching-adjusted indirect treatment comparisons (MAICs). Therefore, an unanchored MAIC was performed using patient level data from bosutinib (BFORE trial) and published aggregated data from nilotinib (ENESTnd) and dasatinib (DASISION) trials. After matching, cytogenetic and molecular responses, and disease progression, after a minimum follow-up of 24 months were compared between nilotinib versus bosutinb and dasatinib versus bosutinib.Results: The comparison of nilotinib versus bosutinib resulted in no statistically significant differences for MMR at and by 24 months, MR4 by 24 months, MR4.5 at and by 24 months, CCyR by 24 months, and disease progression, however, a decreased odds of MR4 at 24 months in favor of bosutinib versus nilotinib was observed. The comparison of dasatinib versus bosutinib by 24 months resulted in no statistically significant differences for MMR, disease progression, and CCyR, however a decreased odds of MR4.5 in favor of bosutinib versus dasatinib was observed.Conclusions: Overall, in these analyses bosutinib demonstrates equivalent efficacy to nilotinib and dasatinib in the treatment of patients with newly diagnosed CP-CML. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. S196: ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM‐3.

Author

Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J, Rodríguez‐Otero, Paula, Martinez‐Lopez, Joaquín, Touzeau, Cyrille, Quach, Hang, Depaus, Julien, Yokoyama, Hisayuki, Manier, Salomon, Raje, Noopur, Raab, Marc S., Searle, Emma, Leip, Eric, Sullivan, Sharon T., Czibere, Akos, Viqueira, Andrea, and Lesokhin, Alexander

Published
2023
Full Text
View/download PDF

38. P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES.

Author

Manier, Salomon, Lesokhin, Alexander, Mohty, Mohamad, Niesvizky, Ruben, Maisel, Christopher, Arnulf, Bertrand, Larson, Sarah M., Nina Varshavsky-Yanovsky, Asya, Leleu, Xavier, Karlin, Lionel, Vesole, David H., Bahlis, Nizar J, Fernandez de Larrea, Carlos, Raje, Noopur, Leip, Eric, Sullivan, Sharon T., Elmeliegy, Mohamed, Viqueira, Andrea, and Nooka, Ajay

Published
2023
Full Text
View/download PDF

44. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

Author

Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Prince, H. Miles, Niesvizky, Ruben, Rodríguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Jethava, Yogesh, Gabayan, A. Eli, Stevens, Don A., Nooka, Ajay K., Raje, Noopur S., Iida, Shinsuke, Leip, Eric, Conte, Umberto, Czibere, Akos Gabor, Viqueira, Andrea, and Lesokhin, Alexander M.

Published
2023
Full Text
View/download PDF

46. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.

Author

Nooka, Ajay K., Lesokhin, Alexander M., Mohty, Mohamad, Niesvizky, Ruben, Maisel, Christopher, Arnulf, Bertrand, Larson, Sarah Marie, Varshavsky Yanovsky, Asya, Leleu, Xavier P, Karlin, Lionel, Vesole, David H., Bahlis, Nizar J., Fernández de Larrea, Carlos, Raje, Noopur S., Leip, Eric, Conte, Umberto, Elmeliegy, Mohamed, Viqueira, Andrea, and Manier, Salomon

Published
2023
Full Text
View/download PDF

47. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.

Author

Gambacorti-Passerini C, Brümmendorf TH, Abruzzese E, Kelly KR, Oehler VG, García-Gutiérrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles FJ, and Hochhaus A

Abstract

This final analysis from the phase 4 BYOND trial reports outcomes with bosutinib in patients with previously treated chronic myeloid leukemia (CML); 163 patients with CML resistant/intolerant to previous tyrosine kinase inhibitors received bosutinib (starting dose: 500 mg QD). At study completion (median follow-up, 47.8 months), 48.1% (n = 75/156) of patients with Philadelphia chromosome-positive chronic phase CML were still receiving treatment. Among evaluable patients, 71.8% (95% CI, 63.9-78.9) and 59.7% (95% CI, 51.4-67.7) attained or maintained major molecular response (MMR) and molecular response (MR) 4 , respectively, at any time on treatment. The majority of patients achieved a deeper molecular response relative to baseline while on bosutinib. Kaplan-Meier probabilities (95% CI) of maintaining MMR and MR 4 at 36 months were 87.2% (78.0-92.7) and 80.7% (69.4-88.1), respectively. At 48 months, the Kaplan-Meier overall survival rate was 88.3% (95% CI, 81.8-92.6); there were 17 deaths, including 2 that were considered CML related. Long-term adverse events (AEs) were consistent with the known safety profile of bosutinib, and no new safety issues were identified. The management of AEs through dose reduction maintained efficacy while improving tolerability. These results support the use of bosutinib in patients with previously treated CML.ClinicalTrials.gov, NCT02228382., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

48. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.

Author

Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Brümmendorf TH, Leip E, Viqueira A, and Gambacorti-Passerini C

Subjects
Humans, Philadelphia Chromosome, Tyrosine Kinase Inhibitors, Imatinib Mesylate therapeutic use, Nitriles therapeutic use, Protein Kinase Inhibitors adverse effects, Leukemia drug therapy, Antineoplastic Agents adverse effects
Published
2023
Full Text
View/download PDF

49. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.

Author

Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, and García-Foncillas J

Subjects
Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Gene Frequency genetics, Genetic Association Studies, Humans, Indoles pharmacology, Kaplan-Meier Estimate, Male, Middle Aged, Models, Genetic, Multivariate Analysis, Pyrroles pharmacology, Sunitinib, Treatment Outcome, Biomarkers, Tumor genetics, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Cyclooxygenase 2 genetics, Indoles therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics, Polymorphism, Single Nucleotide genetics, Pyrroles therapeutic use
Abstract

Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a multicenter, prospective and observational study involving 20 hospitals. Seventy-five mRCC patients treated with sunitinib as first line were used to assess the impact of 63 SNPs in 31 candidate genes on clinical outcome. rs2243250 (IL4) and rs5275 (PTGS2) were found to be significantly associated with shorter cancer-specific survival (CSS). Moreover, allele C (rs5275) was associated with higher PTGS2 expression level confirming its functional role. Combination of rs5275 and rs7651265 or rs2243250 for progression free survival (PFS) or CSS, respectively, was a more valuable predictive biomarker remaining significant after correction for multiple testing. It is the first time that association of rs5275 with survival in mRCC patients is described. Two-SNP models containing this functional variant may serve as more predictive biomarkers for sunitinib and could suppose a clinically relevant tool to improve the mRCC patient management.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results